^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PTK7-targeted antibody-drug conjugate

    Related drugs:
    17d
    A Study of SKB518 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    21d
    A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=76, Not yet recruiting, Kivu Bioscience Inc.
    New P1 trial
    2ms
    Expression of antibody-drug conjugate targets in soft tissue sarcomas. (PubMed, ESMO Open)
    STSs express multiple target genes relevant for ADC treatment and expression varies between and within the pathological types. This comprehensive ADC target landscape, based on the largest molecular epidemiology study in STS, should help clinicians and drug developers for further evaluation of ADCs across STS types.
    Journal • PARP Biomarker • IO biomarker
    |
    PTK7 (Protein Tyrosine Kinase 7)
    2ms
    A Study of LY4175408 in Participants With Advanced Cancer (clinicaltrials.gov)
    P1, N=240, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    3ms
    PRO1107 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=33, Terminated, Genmab | Trial completion date: Jun 2028 --> Aug 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2028 --> Aug 2025; Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation
    Trial completion date • Trial termination • Trial primary completion date
    4ms
    PRO1107 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=42, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting | N=280 --> 42
    Enrollment closed • Enrollment change
    5ms
    An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=65, Active, not recruiting, AbbVie | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    PTK7 (Protein Tyrosine Kinase 7)
    |
    cofetuzumab pelidotin (ABBV-647)
    5ms
    CAR19-T/NK cell and circular aptamer-drug conjugate (ApDC) combination treatment increases immunotherapy efficacy. (PubMed, Mol Cell Biochem)
    A combination therapy composed of C-ApDC nanobodies and CAR19-T/NK cells was successfully developed. This innovative approach effectively enhances the cytotoxicity of CAR19-T/NK cells against tumour cells, providing a novel therapeutic strategy for tumour treatment and offering a promising solution to overcome CAR-T resistance.
    Journal
    |
    PTK7 (Protein Tyrosine Kinase 7)
    5ms
    A Study of LY4175408 in Participants With Advanced Cancer (clinicaltrials.gov)
    P1, N=240, Not yet recruiting, Eli Lilly and Company
    New P1 trial
    6ms
    A Study of SKB518 in Patients With Lung Cancer (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
    New P2 trial
    6ms
    Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy. (PubMed, Mol Cancer Ther)
    This study provides the first investigation of a PTK7-targeting antibody (OI-1) as an antibody-radionuclide conjugate (212Pb-labeled) in a preclinical model of intraperitoneal ovarian cancer. These results support further investigation of OI-1 as a candidate for targeted radionuclide therapy in PTK7-expressing cancers.
    Preclinical • Journal
    |
    PTK7 (Protein Tyrosine Kinase 7)
    7ms
    PRO1107 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=280, Recruiting, Genmab | N=214 --> 280 | Trial completion date: Feb 2027 --> Jun 2028 | Trial primary completion date: Feb 2027 --> Jun 2028
    Enrollment change • Trial completion date • Trial primary completion date